July 6 - a new study published recently in the Journal of internal medicine and emergency medicine provides the first real-world evidence that people switching from cigarettes to British American Tobacco's flagship tobacco heating product glo can significantly reduce their exposure to certain toxic substances and potentially harmful indicators related to several smoking related diseases.
In the 12-month study, results recorded at 6 months showed that a complete switch to glo resulted in statistically significant changes in a range of "exposure biomarkers" (BOE) and potential hazard indicators (known as "potential hazard biomarkers" (boph)) compared with continued smoking.
For most of the biomarkers tested, people who used glo had similar reductions as those who quit smoking completely.
According to the measured toxicants, glo users showed that:
Biomarkers that significantly reduce the risk of lung cancer;
White blood cell count was significantly decreased, which was an inflammatory marker of cardiovascular disease risk (CVD) and other smoking related diseases;
Improvement of HDL-C is associated with lower risk of cardiovascular disease;
Two key indicators to improve lung health;
Improving oxidative stress is a key indicator of this process, which involves some smoking related diseases, such as cardiovascular disease and hypertension.
"These results are exciting because they give us an insight into the potential of using glo completely to reduce risk." David O'Reilly, director of scientific research at bat, said in a statement that smokers switching to glo could reduce their exposure to certain toxic substances, thereby reducing the risk of certain smoking related diseases.
"The significant reduction in boph (some equivalent to quitting smoking altogether) is very encouraging and provides further scientific evidence for glo's potential to reduce harm and how it supports our ambition to build a better tomorrow by reducing the health impact of our business."